Details of the Drug Combinations

General Information of This Drug (ID: DMNFADH)

Drug Name

APR-246 DMNFADH

Synonyms

Eprenetapopt

Indication

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 2	[1]
Bladder cancer	2C94	Phase 1/2	[2]
Gastric adenocarcinoma	2B72	Phase 1/2	[2]
Esophageal cancer	2B70	Phase 1	[1]
Myelodysplastic syndrome	2A37	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Preclinical	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
APR-246 + Panobinostat	DCG4DSU	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
------------------------------------------------------------------------------------

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
APR-246 + Dabrafenib	DC5N5GF	Dabrafenib	Melanoma	[5]
Venetoclax + APR-246	DCVHB79	Venetoclax	Myeloid Malignancy	[6]
Venetoclax + APR-246	DCGU65J	Venetoclax	Recurrent Mantle Cell Lymphoma	[7]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT04383938) Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies. U.S. National Institutes of Health.
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030246)
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5	ClinicalTrials.gov (NCT03391050) A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma
6	ClinicalTrials.gov (NCT04214860) APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
7	ClinicalTrials.gov (NCT04990778) Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma